Leslie D. Funtleyder Sells 22,950 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) Stock

Applied Therapeutics, Inc. (NASDAQ:APLT) insider Leslie D. Funtleyder sold 22,950 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $0.61, for a total value of $13,999.50. Following the sale, the insider now owns 404,961 shares in the company, valued at approximately $247,026.21. The trade was a 5.36 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Applied Therapeutics Price Performance

APLT opened at $0.61 on Friday. The firm has a market capitalization of $70.99 million, a PE ratio of -0.38 and a beta of 1.88. Applied Therapeutics, Inc. has a fifty-two week low of $0.54 and a fifty-two week high of $10.62. The company’s 50-day moving average is $0.90 and its 200 day moving average is $5.14.

Institutional Trading of Applied Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in Applied Therapeutics by 37.8% during the third quarter. Janus Henderson Group PLC now owns 10,541,528 shares of the company’s stock worth $89,656,000 after buying an additional 2,893,323 shares in the last quarter. State Street Corp grew its stake in shares of Applied Therapeutics by 123.1% in the 3rd quarter. State Street Corp now owns 3,694,607 shares of the company’s stock worth $31,404,000 after acquiring an additional 2,038,724 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Applied Therapeutics by 165.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 735,217 shares of the company’s stock worth $6,249,000 after purchasing an additional 457,940 shares in the last quarter. Ally Bridge Group NY LLC purchased a new stake in Applied Therapeutics in the 3rd quarter valued at about $5,256,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of Applied Therapeutics by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock worth $268,000 after buying an additional 47,983 shares in the last quarter. 98.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Robert W. Baird dropped their target price on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, November 29th. William Blair lowered shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, December 23rd. UBS Group restated a “neutral” rating and issued a $2.00 target price (down from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Citigroup dropped their price target on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Finally, Royal Bank of Canada reduced their price objective on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating for the company in a research note on Friday, December 20th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Applied Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.